Clinical trial
Open Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of Allogenic Administration of Treg Cells Obtained From Thymic Tissue (thyTreg) to Control The Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome
NCT06052436 is registered in ClinicalTrials.gov with Hospital General Universitario Gregorio Marañon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of Allogenic Administration of Treg Cells Obtained From Thymic Tissue (thyTreg) to Control The Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome
- Lead sponsor
- Hospital General Universitario Gregorio Marañon
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- June 27, 2023
- Completion date
- December 31, 2027
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.